首页 > 最新文献

Frontiers in drug delivery最新文献

英文 中文
Glucagon-like peptide-1 receptor agonists for treatment of diabetes and obesity: advantage of oral delivery. 治疗糖尿病和肥胖症的胰高血糖素样肽-1受体激动剂:口服给药的优势。
Pub Date : 2024-11-06 eCollection Date: 2024-01-01 DOI: 10.3389/fddev.2024.1456654
R R C New, M Bogus, G N Travers, U Hahn, A Vaiceliunaite, M Burnet, J H Wang, H Wen

GLP-1 receptor agonists ((GLP-1 RAs) are currently receiving a lot of attention because of their impact in diabetes, weight loss and other areas. While GLP-1 RAs in injectable form are highly efficacious, further work is required to develop oral versions which can deliver these peptides efficiently without requiring use of excessively high doses. This paper describes the ability of an oral peptide delivery formulation, Axcess™, to enhance uptake of GLP-1 receptor agonists via the intestine, resulting in changes in insulin and glucose blood levels indicative of biopotencies of 9% for exendin-4 and 14.8% for semaglutide in preclinical models. The route of delivery suggests that the peptides will be able to interact with the GLP-1 receptors on the vagal afferents of the intestine, as is the case for native GLP-1 in healthy individuals. GLP-1 receptor agonists administered via this route will be a valuable addition to the therapeutic modalities available for treatment of diabetes and obesity.

GLP-1受体激动剂(GLP-1 receptor agonists,简称GLP-1 RAs)因其在糖尿病、减肥等领域的作用而受到广泛关注。虽然注射形式的GLP-1 RAs是非常有效的,但需要进一步的工作来开发口服版本,以便在不需要使用过高剂量的情况下有效地递送这些肽。本文描述了口服肽递送制剂axess™的能力,通过肠道增强GLP-1受体激动剂的吸收,导致胰岛素和血糖水平的变化,表明临床前模型中exendin-4和semaglutide的生物效价分别为9%和14.8%。传递途径表明,肽将能够与肠迷走神经传入的GLP-1受体相互作用,就像健康个体的天然GLP-1一样。通过这种途径给药的GLP-1受体激动剂将是治疗糖尿病和肥胖症的一种有价值的治疗方式。
{"title":"Glucagon-like peptide-1 receptor agonists for treatment of diabetes and obesity: advantage of oral delivery.","authors":"R R C New, M Bogus, G N Travers, U Hahn, A Vaiceliunaite, M Burnet, J H Wang, H Wen","doi":"10.3389/fddev.2024.1456654","DOIUrl":"10.3389/fddev.2024.1456654","url":null,"abstract":"<p><p>GLP-1 receptor agonists ((GLP-1 RAs) are currently receiving a lot of attention because of their impact in diabetes, weight loss and other areas. While GLP-1 RAs in injectable form are highly efficacious, further work is required to develop oral versions which can deliver these peptides efficiently without requiring use of excessively high doses. This paper describes the ability of an oral peptide delivery formulation, Axcess™, to enhance uptake of GLP-1 receptor agonists via the intestine, resulting in changes in insulin and glucose blood levels indicative of biopotencies of 9% for exendin-4 and 14.8% for semaglutide in preclinical models. The route of delivery suggests that the peptides will be able to interact with the GLP-1 receptors on the vagal afferents of the intestine, as is the case for native GLP-1 in healthy individuals. GLP-1 receptor agonists administered via this route will be a valuable addition to the therapeutic modalities available for treatment of diabetes and obesity.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"4 ","pages":"1456654"},"PeriodicalIF":0.0,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363265/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial: Women in CNS drug delivery: 2022-2024. 社论:女性参与中枢神经系统给药:2022-2024。
Pub Date : 2024-10-15 eCollection Date: 2024-01-01 DOI: 10.3389/fddev.2024.1400937
Szilvia Veszelka, Malgorzata Burek, Sarah Ann Thomas
{"title":"Editorial: Women in CNS drug delivery: 2022-2024.","authors":"Szilvia Veszelka, Malgorzata Burek, Sarah Ann Thomas","doi":"10.3389/fddev.2024.1400937","DOIUrl":"10.3389/fddev.2024.1400937","url":null,"abstract":"","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"4 ","pages":"1400937"},"PeriodicalIF":0.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363288/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Electrospun patches to deliver combination drug therapy for fungal infections. 静电纺丝贴片为真菌感染提供联合药物治疗。
Pub Date : 2024-09-16 eCollection Date: 2024-01-01 DOI: 10.3389/fddev.2024.1458009
Karolina Dziemidowicz, Mark Meszarik, Jacopo Piovesan, Mazna A Almatroudi, Gareth R Williams, Sudaxshina Murdan

Fungal infections, though affecting healthcare globally, receive insufficient attention in clinical and academic settings. Invasive fungal infections, particularly caused by combat wounds, have been identified as a critical threat by the US Department of Defense. Monotherapy with traditional antifungals is often insufficient, and so combination therapies are explored to enhance treatment efficacy. However, systemic combination treatments can result in severe adverse effects, suggesting the need for localised delivery systems, such as drug-loaded electrospun patches, to administer antifungals directly to the infection site. This proof-of-concept study hypothesised that dual amorolfine and terbinafine therapy slowly releasing from electrospun patches would be an effective way of eradicating Candida albicans when the patch was applied directly to the fungal colony. The feasibility of creating electrospun materials loaded with amorolfine and terbinafine for combination antifungal therapy was investigated. Electrospinning was used to fabricate polycaprolactone (PCL) patches with varying drug loadings (2.5%, 5%, and 10% w/w) of amorolfine and terbinafine either individually or in combination. The incorporation of both drugs in the fibres was confirmed, with the drugs predominantly in an amorphous state. Results showed that combination therapy patches had a significantly greater and prolonged antifungal effect compared to monotherapy patches, with larger zones of inhibition and sustained efficacy over at least 7 days. This study therefore demonstrates that PCL-based electrospun patches containing amorolfine and terbinafine provide superior antifungal activity against C. albicans compared to monotherapy patches. This approach could lower required drug doses, reducing adverse effects, and enhance patient compliance due to prolonged drug release, leading to more effective antifungal therapy.

真菌感染虽然影响着全球的医疗保健,但在临床和学术环境中却得不到足够的重视。侵袭性真菌感染,特别是由战斗伤口引起的,已被美国国防部确定为严重威胁。传统抗真菌药物单药治疗往往不足,因此探索联合治疗以提高治疗效果。然而,全身联合治疗可能导致严重的不良反应,这表明需要局部给药系统,例如载药的静电纺丝贴片,将抗真菌药物直接施用到感染部位。这项概念验证性研究假设,当电纺丝贴片直接应用于真菌菌落时,阿莫罗芬和特比萘芬的双重治疗缓慢释放将是根除白色念珠菌的有效方法。探讨了制备负载阿莫罗芬和特比萘芬的静电纺材料用于联合抗真菌治疗的可行性。采用静电纺丝法制备阿莫罗芬和特比萘芬单独或联合的不同载药量(2.5%、5%和10% w/w)的聚己内酯(PCL)贴片。这两种药物在纤维中的掺入被证实,药物主要处于无定形状态。结果显示,与单一治疗贴片相比,联合治疗贴片具有更大的抗真菌效果和更长的抗真菌效果,具有更大的抑制范围和至少7天的持续疗效。因此,这项研究表明,与单一治疗贴片相比,基于pcl的含有阿莫罗芬和特比萘芬的静电纺丝贴片对白色念珠菌具有更好的抗真菌活性。这种方法可以降低所需的药物剂量,减少不良反应,并由于药物释放时间延长而提高患者的依从性,从而导致更有效的抗真菌治疗。
{"title":"Electrospun patches to deliver combination drug therapy for fungal infections.","authors":"Karolina Dziemidowicz, Mark Meszarik, Jacopo Piovesan, Mazna A Almatroudi, Gareth R Williams, Sudaxshina Murdan","doi":"10.3389/fddev.2024.1458009","DOIUrl":"10.3389/fddev.2024.1458009","url":null,"abstract":"<p><p>Fungal infections, though affecting healthcare globally, receive insufficient attention in clinical and academic settings. Invasive fungal infections, particularly caused by combat wounds, have been identified as a critical threat by the US Department of Defense. Monotherapy with traditional antifungals is often insufficient, and so combination therapies are explored to enhance treatment efficacy. However, systemic combination treatments can result in severe adverse effects, suggesting the need for localised delivery systems, such as drug-loaded electrospun patches, to administer antifungals directly to the infection site. This proof-of-concept study hypothesised that dual amorolfine and terbinafine therapy slowly releasing from electrospun patches would be an effective way of eradicating <i>Candida albicans</i> when the patch was applied directly to the fungal colony. The feasibility of creating electrospun materials loaded with amorolfine and terbinafine for combination antifungal therapy was investigated. Electrospinning was used to fabricate polycaprolactone (PCL) patches with varying drug loadings (2.5%, 5%, and 10% w/w) of amorolfine and terbinafine either individually or in combination. The incorporation of both drugs in the fibres was confirmed, with the drugs predominantly in an amorphous state. Results showed that combination therapy patches had a significantly greater and prolonged antifungal effect compared to monotherapy patches, with larger zones of inhibition and sustained efficacy over at least 7 days. This study therefore demonstrates that PCL-based electrospun patches containing amorolfine and terbinafine provide superior antifungal activity against <i>C. albicans</i> compared to monotherapy patches. This approach could lower required drug doses, reducing adverse effects, and enhance patient compliance due to prolonged drug release, leading to more effective antifungal therapy.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"4 ","pages":"1458009"},"PeriodicalIF":0.0,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363251/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144980999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A selective review of inhibitors of protein kinase C gamma: a neuroplasticity-related common pathway for psychiatric illness. 蛋白激酶C γ抑制剂的选择性回顾:精神疾病的神经可塑性相关的共同途径。
Pub Date : 2024-09-13 eCollection Date: 2024-01-01 DOI: 10.3389/fddev.2024.1364037
Marco Grados, Mona Salehi, Aida Lotfi, Sagar Dua, Isabella Xie

Psychotropics are currently developed and marketed with a limited understanding of their mechanism of action. The notion that protein kinase C (PKC) activity is highly relevant to learning and memory function stems from experiments in the 1980s, which associated protein kinase alpha (pka) and pkc to animal models of associative learning, opening an area of exploration for psychotropic development. The PKC family consists of several isoforms, including PKC alpha, beta1, beta1, gamma, delta and epsilon among others. In particular, PKC gamma (PRKCG) is highly brain-expressed and is singled out as a candidate for modulation in psychiatric illness. With hundreds of identified substrates, PRKCG affects multiple pathways relevant for regulation of neuronal health. In this review, converging lines of evidence are presented in the context of psychotropic drug action, which point to downregulation of PKC activity as a potential common mechanism across several psychiatric disorders. Using this mechanism through more targeted psychotropic action may then be used to develop agents that further ameliorate psychiatric symptom expression. Psychotropics including fluoxetine, tricyclics, lithium, valproate, ketamine and others are explored in relation to their effect of PKC, finding that across all drugs examined, a downregulation with chronic-but not acute-use constitutes their putative effect in ameliorating symptoms. This effect is compounded by findings that suggest that PKCs, and PRKCG in particular, promote neuroplastic effects by their downregulation. This effect is in contrast to PKC activators, which have been used in neurodegenerative disorders such as Alzheimer's disease. Cross-disorder mechanisms need to continue to be explored in neuropsychiatric illness and targeted treatments developed in turn to address treatment-resistant conditions.

目前,精神药物的开发和销售对其作用机制的了解有限。蛋白激酶C (PKC)活性与学习和记忆功能高度相关的概念源于20世纪80年代的实验,该实验将蛋白激酶α (pka)和PKC与联想学习的动物模型联系起来,为精神药物的开发开辟了一个探索领域。PKC家族由几个同工异构体组成,包括PKC α, beta1, beta1, gamma, delta和epsilon等。特别是,PKC γ (PRKCG)在大脑中高度表达,被认为是精神疾病调节的候选基因。通过数百种已确定的底物,PRKCG影响与神经元健康调节相关的多种途径。在这篇综述中,在精神药物作用的背景下提出了越来越多的证据,这些证据表明PKC活性的下调是几种精神疾病的潜在共同机制。利用这一机制,通过更有针对性的精神药物作用,可以用来开发进一步改善精神症状表达的药物。精神药物包括氟西汀、三环类药物、锂、丙戊酸盐、氯胺酮和其他药物,研究人员对它们对PKC的影响进行了探索,发现在所有被检查的药物中,慢性而非急性使用的下调构成了它们在改善症状方面的假定效果。研究结果表明,PKCs,特别是PRKCG,通过下调来促进神经可塑性作用,这一效应更加复杂。这种效果与PKC激活剂相反,PKC激活剂已用于神经退行性疾病,如阿尔茨海默病。需要继续探索神经精神疾病的交叉障碍机制,并开发靶向治疗来解决治疗抵抗性疾病。
{"title":"A selective review of inhibitors of protein kinase C gamma: a neuroplasticity-related common pathway for psychiatric illness.","authors":"Marco Grados, Mona Salehi, Aida Lotfi, Sagar Dua, Isabella Xie","doi":"10.3389/fddev.2024.1364037","DOIUrl":"10.3389/fddev.2024.1364037","url":null,"abstract":"<p><p>Psychotropics are currently developed and marketed with a limited understanding of their mechanism of action. The notion that protein kinase C (PKC) activity is highly relevant to learning and memory function stems from experiments in the 1980s, which associated protein kinase alpha (pka) and pkc to animal models of associative learning, opening an area of exploration for psychotropic development. The PKC family consists of several isoforms, including PKC alpha, beta1, beta1, gamma, delta and epsilon among others. In particular, PKC gamma (PRKCG) is highly brain-expressed and is singled out as a candidate for modulation in psychiatric illness. With hundreds of identified substrates, PRKCG affects multiple pathways relevant for regulation of neuronal health. In this review, converging lines of evidence are presented in the context of psychotropic drug action, which point to downregulation of PKC activity as a potential common mechanism across several psychiatric disorders. Using this mechanism through more targeted psychotropic action may then be used to develop agents that further ameliorate psychiatric symptom expression. Psychotropics including fluoxetine, tricyclics, lithium, valproate, ketamine and others are explored in relation to their effect of PKC, finding that across all drugs examined, a downregulation with chronic-but not acute-use constitutes their putative effect in ameliorating symptoms. This effect is compounded by findings that suggest that PKCs, and PRKCG in particular, promote neuroplastic effects by their downregulation. This effect is in contrast to PKC activators, which have been used in neurodegenerative disorders such as Alzheimer's disease. Cross-disorder mechanisms need to continue to be explored in neuropsychiatric illness and targeted treatments developed in turn to address treatment-resistant conditions.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"4 ","pages":"1364037"},"PeriodicalIF":0.0,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363335/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preclinical evaluation of a novel antibiotic-eluting BioEnvelope for CIED infection prevention. 新型抗生素洗脱生物包膜预防CIED感染的临床前评价。
Pub Date : 2024-09-10 eCollection Date: 2024-01-01 DOI: 10.3389/fddev.2024.1441956
Zerelda Esquer Garrigos, John N Catanzaro, Daniel Deegan, Ji Zhang, M Rizwan Sohail

The risk of infection remains a significant concern with cardiovascular implantable electronic devices, necessitating the development of new strategies. This study explores the efficacy of a novel antibiotic-eluting biologic envelope designed to mitigate infection risk through localized antibiotic delivery while preserving the regenerative properties of biological matrix. Antibiotics, rifampin and minocycline, are released through polymer discs, ensuring extended drug release. Utilizing an established model of infection in a New Zealand White rabbit, the study assessed performance against Gram-positive bacterial strains, including common pathogens such as Staphylococcus aureus and S. epidermidis associated with CIED infections, and Gram-negative bacterial strains. Results demonstrated strong antibacterial activity, achieving complete eradication of bacterial colonies and greater than 6-log reductions in colonization for all strains. Pharmacokinetic analysis revealed sustained local antibiotic concentrations at the implantation site for up to 14 days, with minimal systemic exposure, demonstrating the advantages of localized drug delivery. Health outcomes in the antibiotic bioenvelope group were significantly improved, with no signs of infection or abnormal body temperatures, in contrast to the control group. Macroscopic examinations post-necropsy confirmed the absence of infection at the implantation sites of animals receiving the antibiotic bioenvelope. The combination of localized antibiotic delivery in a regenerative matrix positions the antibiotic bioenvelope as a promising solution for preventing CIED-related infections.

感染风险仍然是心血管植入式电子设备的一个重要问题,需要开发新的策略。本研究探讨了一种新型抗生素洗脱生物包膜的功效,该生物包膜旨在通过局部抗生素递送来降低感染风险,同时保留生物基质的再生特性。抗生素,利福平和米诺环素,通过聚合物光盘释放,确保延长药物释放。利用已建立的新西兰大白兔感染模型,该研究评估了对革兰氏阳性菌株的性能,包括与CIED感染相关的常见病原体,如金黄色葡萄球菌和表皮葡萄球菌,以及革兰氏阴性菌株。结果显示出很强的抗菌活性,可以完全根除细菌菌落,并且所有菌株的定植量都减少了6倍以上。药代动力学分析显示,植入部位的局部抗生素浓度可维持长达14天,而全身暴露最少,证明了局部给药的优势。与对照组相比,抗生素生物包膜组的健康状况明显改善,没有感染迹象或体温异常。尸检后的肉眼检查证实,在接受抗生素生物包膜的动物植入部位没有感染。在再生基质中结合局部抗生素递送使抗生素生物包膜成为预防cied相关感染的有希望的解决方案。
{"title":"Preclinical evaluation of a novel antibiotic-eluting BioEnvelope for CIED infection prevention.","authors":"Zerelda Esquer Garrigos, John N Catanzaro, Daniel Deegan, Ji Zhang, M Rizwan Sohail","doi":"10.3389/fddev.2024.1441956","DOIUrl":"10.3389/fddev.2024.1441956","url":null,"abstract":"<p><p>The risk of infection remains a significant concern with cardiovascular implantable electronic devices, necessitating the development of new strategies. This study explores the efficacy of a novel antibiotic-eluting biologic envelope designed to mitigate infection risk through localized antibiotic delivery while preserving the regenerative properties of biological matrix. Antibiotics, rifampin and minocycline, are released through polymer discs, ensuring extended drug release. Utilizing an established model of infection in a New Zealand White rabbit, the study assessed performance against Gram-positive bacterial strains, including common pathogens such as <i>Staphylococcus aureus</i> and <i>S. epidermidis</i> associated with CIED infections, and Gram-negative bacterial strains. Results demonstrated strong antibacterial activity, achieving complete eradication of bacterial colonies and greater than 6-log reductions in colonization for all strains. Pharmacokinetic analysis revealed sustained local antibiotic concentrations at the implantation site for up to 14 days, with minimal systemic exposure, demonstrating the advantages of localized drug delivery. Health outcomes in the antibiotic bioenvelope group were significantly improved, with no signs of infection or abnormal body temperatures, in contrast to the control group. Macroscopic examinations post-necropsy confirmed the absence of infection at the implantation sites of animals receiving the antibiotic bioenvelope. The combination of localized antibiotic delivery in a regenerative matrix positions the antibiotic bioenvelope as a promising solution for preventing CIED-related infections.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"4 ","pages":"1441956"},"PeriodicalIF":0.0,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dual conjugation of magnetic nanoparticles with antibodies and siRNA for cell-specific gene silencing in vascular cells. 磁性纳米颗粒与抗体和siRNA的双偶联用于血管细胞特异性基因沉默。
Pub Date : 2024-08-15 eCollection Date: 2024-01-01 DOI: 10.3389/fddev.2024.1416737
Katarzyna Karpinska, Lin Li, Tao Wang

RNA therapy is a rapidly expanding field and has great promise in achieving targeted gene silencing and contributing to personalized medicine. However, the delivery of RNA molecules into targeted organs or cells is still challenging. To overcome this hurdle, a number of nanocarriers with pros and cons have been developed. This study was designed to develop a simple and cost-effective approach to functionalize biodegradable magnetic iron nanoparticles (MNPs) for cell-specific siRNA delivery. MNPs were synthesized based on co-precipitation and further functionalized with sodium citrate and polyethyleneimine (PEI) followed by material characterization using TEM, FTIR, and Zeta potential. The citrate and PEI-coated MNPs were further conjugated with CD31 antibody and complexed with siRNA using a linker-free approach. siRNA-loaded MNPs successfully knocked down the expression of GAPDH in human endothelial cells (ECs) and NOTCH3 in human vascular smooth muscle cells (VSMCs). In an EC and VSMC co-culture system under shear stress to mimic blood flow, siRNA and CD31 conjugated MNPs specifically targeted and delivered siRNA into the ECs. Our approach represents a versatile platform that could be adopted for targeted general siRNA delivery.

RNA治疗是一个快速发展的领域,在实现靶向基因沉默和个性化医疗方面有很大的希望。然而,将RNA分子运送到目标器官或细胞中仍然具有挑战性。为了克服这一障碍,已经开发了许多具有优缺点的纳米载体。本研究旨在开发一种简单而经济的方法来功能化可生物降解的磁性铁纳米颗粒(MNPs),用于细胞特异性siRNA的递送。采用共沉淀法合成了MNPs,并用柠檬酸钠和聚乙烯亚胺(PEI)进行了功能化,并利用TEM、FTIR和Zeta电位对材料进行了表征。柠檬酸盐和pei包被的MNPs进一步与CD31抗体结合,并使用无连接体的方法与siRNA络合。装载sirna的MNPs成功地敲低了人内皮细胞(ECs)中GAPDH的表达和人血管平滑肌细胞(VSMCs)中NOTCH3的表达。在剪切应力下模拟血流的EC和VSMC共培养系统中,siRNA和CD31结合的MNPs特异性靶向并将siRNA递送到EC中。我们的方法代表了一个多功能平台,可以用于靶向一般siRNA递送。
{"title":"Dual conjugation of magnetic nanoparticles with antibodies and siRNA for cell-specific gene silencing in vascular cells.","authors":"Katarzyna Karpinska, Lin Li, Tao Wang","doi":"10.3389/fddev.2024.1416737","DOIUrl":"10.3389/fddev.2024.1416737","url":null,"abstract":"<p><p>RNA therapy is a rapidly expanding field and has great promise in achieving targeted gene silencing and contributing to personalized medicine. However, the delivery of RNA molecules into targeted organs or cells is still challenging. To overcome this hurdle, a number of nanocarriers with pros and cons have been developed. This study was designed to develop a simple and cost-effective approach to functionalize biodegradable magnetic iron nanoparticles (MNPs) for cell-specific siRNA delivery. MNPs were synthesized based on co-precipitation and further functionalized with sodium citrate and polyethyleneimine (PEI) followed by material characterization using TEM, FTIR, and Zeta potential. The citrate and PEI-coated MNPs were further conjugated with CD31 antibody and complexed with siRNA using a linker-free approach. siRNA-loaded MNPs successfully knocked down the expression of <i>GAPDH</i> in human endothelial cells (ECs) and <i>NOTCH3</i> in human vascular smooth muscle cells (VSMCs). In an EC and VSMC co-culture system under shear stress to mimic blood flow, siRNA and CD31 conjugated MNPs specifically targeted and delivered siRNA into the ECs. Our approach represents a versatile platform that could be adopted for targeted general siRNA delivery.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"4 ","pages":"1416737"},"PeriodicalIF":0.0,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363332/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144980984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Strategies and delivery systems for cell-based therapy in autoimmunity 自体免疫细胞疗法的策略和输送系统
Pub Date : 2024-08-08 DOI: 10.3389/fddev.2024.1436842
M. Puccetti, Claudio Costantini, A. Schoubben, S. Giovagnoli, Maurizio Ricci
This review article explores the potential of engineering antigen-presenting cells (APCs) for the immunotherapy of autoimmune diseases. It discusses various strategies for modifying APCs to induce antigen-specific tolerance, thereby mitigating autoimmune responses. The review covers recent advancements in APC engineering techniques, including genetic modification and nanoparticle-based approaches, and evaluates their efficacy in preclinical models and clinical trials. Additionally, challenges and future directions for the development of APC-based immunotherapies for autoimmunity – and other forms of cell-based immunotherapy – are discussed. Along this direction, this review (i) describes various strategies for engineering APCs, including genetic modification, nanoparticle delivery systems, and ex vivo manipulation techniques; (ii) discusses the selection of target antigens and the design of APC-based immunotherapies, and (iii) reviews preclinical models used to evaluate the efficacy and safety of engineered APCs in inducing antigen-specific tolerance.
这篇综述文章探讨了工程化抗原递呈细胞(APCs)用于自身免疫性疾病免疫疗法的潜力。文章讨论了改造抗原递呈细胞以诱导抗原特异性耐受,从而减轻自身免疫反应的各种策略。综述涵盖了 APC 工程技术的最新进展,包括基因修饰和基于纳米粒子的方法,并评估了它们在临床前模型和临床试验中的疗效。此外,还讨论了开发基于 APC 的自身免疫免疫疗法(以及其他形式的细胞免疫疗法)所面临的挑战和未来发展方向。沿着这一方向,本综述(i)介绍了工程化 APCs 的各种策略,包括基因修饰、纳米颗粒递送系统和体外操作技术;(ii)讨论了目标抗原的选择和基于 APC 的免疫疗法的设计;(iii)回顾了用于评估工程化 APCs 在诱导抗原特异性耐受方面的有效性和安全性的临床前模型。
{"title":"Strategies and delivery systems for cell-based therapy in autoimmunity","authors":"M. Puccetti, Claudio Costantini, A. Schoubben, S. Giovagnoli, Maurizio Ricci","doi":"10.3389/fddev.2024.1436842","DOIUrl":"https://doi.org/10.3389/fddev.2024.1436842","url":null,"abstract":"This review article explores the potential of engineering antigen-presenting cells (APCs) for the immunotherapy of autoimmune diseases. It discusses various strategies for modifying APCs to induce antigen-specific tolerance, thereby mitigating autoimmune responses. The review covers recent advancements in APC engineering techniques, including genetic modification and nanoparticle-based approaches, and evaluates their efficacy in preclinical models and clinical trials. Additionally, challenges and future directions for the development of APC-based immunotherapies for autoimmunity – and other forms of cell-based immunotherapy – are discussed. Along this direction, this review (i) describes various strategies for engineering APCs, including genetic modification, nanoparticle delivery systems, and ex vivo manipulation techniques; (ii) discusses the selection of target antigens and the design of APC-based immunotherapies, and (iii) reviews preclinical models used to evaluate the efficacy and safety of engineered APCs in inducing antigen-specific tolerance.","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"14 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141927430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum: Core-shell 3D printed biodegradable calcium phosphate cement - Alginate scaffolds for possible bone regeneration applications. 勘误:核壳3D打印可生物降解磷酸钙水泥-海藻酸盐支架可能的骨再生应用。
Pub Date : 2024-07-18 eCollection Date: 2024-01-01 DOI: 10.3389/fddev.2024.1452132
Clara Schweiker, Sergej Zankovic, Anna Baghnavi, Dirk Velten, Hagen Schmal, Ralf Thomann, Michael Seidenstuecker

[This corrects the article DOI: 10.3389/fddev.2024.1407304.].

[这更正了文章DOI: 10.3389/fddev.2024.1407304.]。
{"title":"Corrigendum: Core-shell 3D printed biodegradable calcium phosphate cement - Alginate scaffolds for possible bone regeneration applications.","authors":"Clara Schweiker, Sergej Zankovic, Anna Baghnavi, Dirk Velten, Hagen Schmal, Ralf Thomann, Michael Seidenstuecker","doi":"10.3389/fddev.2024.1452132","DOIUrl":"10.3389/fddev.2024.1452132","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/fddev.2024.1407304.].</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"4 ","pages":"1452132"},"PeriodicalIF":0.0,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144980969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preliminary results on novel adjuvant combinations suggest enhanced immunogenicity of whole inactivated pandemic influenza vaccines 新型佐剂组合的初步结果表明,全灭活大流行性流感疫苗的免疫原性有所增强
Pub Date : 2024-07-16 DOI: 10.3389/fddev.2024.1382266
Allegra Peletta, Aurélie Marmy, Samo Guzelj, Alcidia Ramos Barros, Ž. Jakopin, Gerrit Borchard
Due to the inherent risk of a further pandemic influenza outbreak, there is a need and growing interest in investigating combinations of prophylactic vaccines and novel adjuvants, particularly to achieve antigen dose sparing and improved immunogenicity. Influenza is a highly variable virus, where the specific vaccine target is constantly changing, representing a major challenge to influenza vaccine development. Currently, commercial inactivated influenza vaccines have a poor CD8+ T response, which impacts cross-reactivity and the duration of response. Adjuvanted influenza vaccines can increase immune responses, thereby achieving better protection and cross-reactivity to help contain the spread of the disease. An early exploration of a hybrid cholesterol-PLGA nanoparticle delivery system containing the saponin tomatine and a NOD2 (nucleotide-binding oligomerization domain 2) agonist called SG101 was conducted. This combination was preliminarily evaluated for its ability to induce cellular immunity when combined with whole inactivated virus (WIV) influenza vaccine. After the adjuvants were manufactured using a single emulsion process, two formulations with different drug loadings were selected and physico-chemically characterized, showing sizes between 224 ± 32 and 309 ± 45 nm and different morphologies. After ensuring the lack of in vitro toxicity and hemolytic activity, a pilot in vivo assay evaluated the hybrid nanoparticle formulation for its ability to induce humoral and cellular immunity when combined with whole inactivated virus (WIV) H5N1 influenza vaccine by intramuscular administration in mice. Hemagglutinin inhibition (HAI) titers for adjuvanted groups showed no significant difference compared to the group vaccinated with the antigen alone. It was similar for CD4+ and CD8+ T cell responses, although the high drug loading formulation induced higher titers of IFNγ-positive CD8+ T cells. These proof-of-concept results encourage further investigations to develop the hybrid formulation with increased or different loading ratios, to investigate manufacturing optimization, and to evaluate the role of the individual immunostimulatory compounds in immune responses.
由于流感大流行爆发的内在风险,人们需要研究预防性疫苗和新型佐剂的组合,特别是实现抗原剂量稀释和提高免疫原性,而且这种研究的兴趣日益浓厚。流感是一种高度易变的病毒,特定的疫苗靶点不断变化,这对流感疫苗的开发是一个重大挑战。目前,商用灭活流感疫苗的 CD8+ T 反应较差,影响交叉反应和反应持续时间。添加佐剂的流感疫苗可以提高免疫反应,从而获得更好的保护和交叉反应,有助于遏制疾病的传播。我们对含有皂素番茄碱和名为 SG101 的 NOD2(核苷酸结合寡聚化结构域 2)激动剂的胆固醇-PLGA 混合纳米颗粒递送系统进行了早期探索。初步评估了这种组合与全灭活病毒(WIV)流感疫苗结合使用时诱导细胞免疫的能力。在使用单一乳液工艺制造佐剂后,选择了两种不同药物载量的制剂,并对其进行了物理化学表征,结果显示这两种制剂的尺寸介于 224 ± 32 nm 和 309 ± 45 nm 之间,形态各异。在确保无体外毒性和溶血活性后,一项试验性体内试验评估了混合纳米颗粒配方与全灭活病毒(WIV)H5N1 流感疫苗结合后在小鼠体内肌肉注射诱导体液免疫和细胞免疫的能力。添加佐剂组的血凝素抑制滴度(HAI)与单独接种抗原组相比无显著差异。CD4+ 和 CD8+ T 细胞反应相似,但高药物载量配方诱导的 IFNγ 阳性 CD8+ T 细胞滴度更高。这些概念验证结果鼓励人们进一步研究开发增加或改变负载率的混合制剂,研究生产优化,并评估单个免疫刺激化合物在免疫反应中的作用。
{"title":"Preliminary results on novel adjuvant combinations suggest enhanced immunogenicity of whole inactivated pandemic influenza vaccines","authors":"Allegra Peletta, Aurélie Marmy, Samo Guzelj, Alcidia Ramos Barros, Ž. Jakopin, Gerrit Borchard","doi":"10.3389/fddev.2024.1382266","DOIUrl":"https://doi.org/10.3389/fddev.2024.1382266","url":null,"abstract":"Due to the inherent risk of a further pandemic influenza outbreak, there is a need and growing interest in investigating combinations of prophylactic vaccines and novel adjuvants, particularly to achieve antigen dose sparing and improved immunogenicity. Influenza is a highly variable virus, where the specific vaccine target is constantly changing, representing a major challenge to influenza vaccine development. Currently, commercial inactivated influenza vaccines have a poor CD8+ T response, which impacts cross-reactivity and the duration of response. Adjuvanted influenza vaccines can increase immune responses, thereby achieving better protection and cross-reactivity to help contain the spread of the disease. An early exploration of a hybrid cholesterol-PLGA nanoparticle delivery system containing the saponin tomatine and a NOD2 (nucleotide-binding oligomerization domain 2) agonist called SG101 was conducted. This combination was preliminarily evaluated for its ability to induce cellular immunity when combined with whole inactivated virus (WIV) influenza vaccine. After the adjuvants were manufactured using a single emulsion process, two formulations with different drug loadings were selected and physico-chemically characterized, showing sizes between 224 ± 32 and 309 ± 45 nm and different morphologies. After ensuring the lack of in vitro toxicity and hemolytic activity, a pilot in vivo assay evaluated the hybrid nanoparticle formulation for its ability to induce humoral and cellular immunity when combined with whole inactivated virus (WIV) H5N1 influenza vaccine by intramuscular administration in mice. Hemagglutinin inhibition (HAI) titers for adjuvanted groups showed no significant difference compared to the group vaccinated with the antigen alone. It was similar for CD4+ and CD8+ T cell responses, although the high drug loading formulation induced higher titers of IFNγ-positive CD8+ T cells. These proof-of-concept results encourage further investigations to develop the hybrid formulation with increased or different loading ratios, to investigate manufacturing optimization, and to evaluate the role of the individual immunostimulatory compounds in immune responses.","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"6 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141640751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Induction of P-glycoprotein overexpression in brain endothelial cells as a model to study blood-brain barrier efflux transport 在脑内皮细胞中诱导 P 糖蛋白过表达,以此作为研究血脑屏障外流转运的模型
Pub Date : 2024-07-05 DOI: 10.3389/fddev.2024.1433453
Sarah F. Hathcock, Hallie E. Knight, Emma G. Tong, Alexandra E. Meyer, Henry D. Mauser, Nadine Vollmuth, Brandon J. Kim
The blood-brain barrier (BBB) is comprised of specialized brain endothelial cells (BECs) that contribute to maintaining central nervous system (CNS) homeostasis. BECs possess properties such as an array of multi-drug efflux transporters that eject various drugs and toxins, preventing their entry into the CNS. Together, it is estimated that these efflux transporters can eject up to 98% of known xenobiotic compounds. P-glycoprotein (P-gp) is a promiscuous efflux transporter at the BBB and can efflux up to 90 various substrates, representing a major hurdle in CNS drug delivery for therapeutic interventions. This necessitates the study of P-gp to discover drugs that are non-substrates of P-gp as well as to identify novel P-gp inhibitors. Here we report the generation of P-gp overexpressing BECs under the endogenous promoter control that could be used in the screening of P-gp substrates. These cells could provide utility in the design of drugs or identification of novel inhibitors.
血脑屏障(BBB)由特化的脑内皮细胞(BEC)组成,有助于维持中枢神经系统(CNS)的平衡。脑内皮细胞具有多种药物外排转运体等特性,可将各种药物和毒素排出体外,阻止它们进入中枢神经系统。据估计,这些外排转运体可将高达 98% 的已知异生物化合物排出体外。P-糖蛋白(P-gp)是中枢神经系统胆红素屏障(BBB)上一种杂乱的外排转运体,可外排多达 90 种不同的底物,是中枢神经系统药物输送治疗干预的一大障碍。因此有必要对 P-gp 进行研究,以发现非 P-gp 底物的药物,并确定新型 P-gp 抑制剂。在此,我们报告了在内源性启动子控制下生成的 P-gp 过表达 BECs,这些细胞可用于筛选 P-gp 底物。这些细胞可用于设计药物或鉴定新型抑制剂。
{"title":"Induction of P-glycoprotein overexpression in brain endothelial cells as a model to study blood-brain barrier efflux transport","authors":"Sarah F. Hathcock, Hallie E. Knight, Emma G. Tong, Alexandra E. Meyer, Henry D. Mauser, Nadine Vollmuth, Brandon J. Kim","doi":"10.3389/fddev.2024.1433453","DOIUrl":"https://doi.org/10.3389/fddev.2024.1433453","url":null,"abstract":"The blood-brain barrier (BBB) is comprised of specialized brain endothelial cells (BECs) that contribute to maintaining central nervous system (CNS) homeostasis. BECs possess properties such as an array of multi-drug efflux transporters that eject various drugs and toxins, preventing their entry into the CNS. Together, it is estimated that these efflux transporters can eject up to 98% of known xenobiotic compounds. P-glycoprotein (P-gp) is a promiscuous efflux transporter at the BBB and can efflux up to 90 various substrates, representing a major hurdle in CNS drug delivery for therapeutic interventions. This necessitates the study of P-gp to discover drugs that are non-substrates of P-gp as well as to identify novel P-gp inhibitors. Here we report the generation of P-gp overexpressing BECs under the endogenous promoter control that could be used in the screening of P-gp substrates. These cells could provide utility in the design of drugs or identification of novel inhibitors.","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":" 21","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141677182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Frontiers in drug delivery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1